Načítá se...
Single dose oral rofecoxib for acute postoperative pain in adults
BACKGROUND: Editor's note: The anti‐inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long‐term use (greater than 18 months) could increase the risk of heart attack and stroke in a study of secondary prevention of adenoma recu...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2009
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4171390/ https://ncbi.nlm.nih.gov/pubmed/19821329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004604.pub3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|